Docket No. ORT-1527

MAY 1 4 2004 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Thomas P. Burris, et. al.

Serial No.: 09/990,461

Art Unit: 1624

Filed

: November 21, 2001


Examiner: Richard L. Raymond

For

: BIOLOGICALLY ACTIVE 4h-BENZO [1,4] OXAZIN-3-ONES-3-

ONES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, F.O. Box 1450, Alexandria, VA 22313-1450 on



Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

\[
\textstyle \te

In accordance with \$1.97(b), since this Information
Disclosure Statement is being filed either within three months of
the filing date of the above-identified national application
(other than a continued prosecution application under §1.53(d)),
within three months of the date of entry into the national stage
of the above identified application as set forth in \$1.491, or
before the mailing date of a first Office Action on the merits of
the above-identified application, or before the mailing date of a
first Office Action after the filing of a request for continued
examination under \$1.114, no additional fee is required.
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with [] the
first or second After Final Submission, therefore:
<pre>Statement in Accordance with \$1.97(e) (attached);</pre>
or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth in
§1.17(p).
F7 - 1 1 51 07 (a) this Information
In accordance with \$1.97(c), this Information
Disclosure Statement is being filed after the period set forth in
§1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or an
action that otherwise closes prosecution and that it is
accompanied by one of:
Statement in Accordance with §1.97(e) (attached);
or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth in
§1.17(p).

	In accordance with \$1.97(d), this Information						
	Disclosure Statement is being filed after the mailing date of						
	either a Final Action under \$1.113 or a Notice of Allowance under						
	§1.311 but before the payment of the Issue Fee. Applicant(s)						
	hereby petition(s) for consideration of this Information						
	Disclosure Statement. Included are: Statement in Accordance with						
	\$1.97(e) as set forth below and the fee of $$180.00$ as set forth in						
	§1.17(p).						
	Copies of each of the references listed on the attached						
	Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.						
	Form P10-1445 are encrosed herewich.						
	Copies of references listed on the attached Form PTO-						
	1449 are enclosed herewith EXCEPT THAT:						
	In view of the voluminous nature of references						
	[list as appropriate], and the likelihood that						
	these references are available to the Examiner,						
	copies are not enclosed herewith.						
	If any of the foregoing publications are not						
	available to the Examiner, Applicant will endeavor						
	to supply copies at the Examiner's request.						
	Copies of only foreign patent documents and non-patent						
	literature are enclosed in accordance with 37 CFR 1.98 (a)(2).						
	(The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35						
•	USC \$371 after June 30, 2003 (see USPTO waiver of requirement						
	under 37 CFR 1.98 (a)(2)(i).						

.

.

Under the report

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 1

a concession of information arrived it deployed a raise constant and a second			
Application Number	09/990,461		
Filing Date	November 21, 2001		
First Named Inventor	Thomas P. Burris		
Group Art Unit	1624		
Examiner Name	Richard L. Raymond		
Attorney Docket Number	ORT-1527		

Examiner's Initials* Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published HILLIARD, JAMESE J. et al. 'Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems' ANTIMICROB. AGENTS CHEMOTHER. (1999), 43(7), 1693-1699, XP002171516 the whole document, especially page 1695, fig.1	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Initials* No. Dublisher, city and/or country where published HILLIARD, JAMESE J. et al. "Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems" ANTIMICROB. AGENTS CHEMOTHER. (1999), 43(7), 1693-1699, XP002171516 the whole			Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	2		
HILLIARD, JAMESE J. et. al. "Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems" ANTIMICROB. AGENTS CHEMOTHER. (1999), 43(7), 1693-1699, XP002171516 the whole			(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	'-		
component systems" ANTIMICROB. AGENTS CHEMOTHER. (1999), 43(7), 1693-1699, XP002171516 the whole	Initials"	NO.	publisher, city and/or country where published			
			component systems ANTIMICROB. AGENTS CHEMOTHER. (1999), 43(7), 1693-1699, XP002171516 the whole			
				 		
		·				
						
		ļl		 		
				 		
				 		
				 		
	 					
				 		
	 			<u> </u>		
		 		 		
		 				
				 		
	 	ļ		 		

	 	والمتراث
Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.